secwatch.observer — SEC 8-K summary
======================================

Issuer:     ARS Pharmaceuticals, Inc. (SPRY)
CIK:        0001671858
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000950170-24-034678
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ARS Pharma to submit CRL response in early Q2 2024; Q4 net loss $7.2M, cash $228.4M
--------------------------------------------------------------------------------

- CRL response for neffy (epinephrine nasal spray) to be submitted early Q2 2024; FDA action and potential launch expected H2 2024.
- Phase 2 urticaria trial met primary endpoints with rapid symptom control; outpatient study planned later in 2024.
- Cash, equivalents and short-term investments $228.4M as of Dec 31, 2023; runway at least three years.
- Net loss $7.2M in Q4, $54.4M full year 2023; R&D costs $3.4M in Q4, G&A $6.8M.
- EMA MAA decision for neffy expected mid-2024; new U.S. patent issued covering intranasal epinephrine methods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671858/000095017024034678/0000950170-24-034678-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671858/000095017024034678/spry-20240321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034678

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer